Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juniperus scopulorum pollen extract is a non-standardized allergenic biologic derived from the pollen of the Rocky Mountain juniper tree. It is indicated for the skin test diagnosis of patients with a clinical history of allergy to juniper pollen and for use in allergen immunotherapy. In diagnostic applications, the extract is used to elicit a wheal-and-flare response in sensitive individuals by cross-linking allergen-specific IgE on mast cells. For therapeutic use, it is administered subcutaneously in increasing doses to induce immunological tolerance, typically characterized by a shift from a Th2-dominated allergic response to a Th1/Treg-mediated response, thereby reducing symptoms of allergic rhinitis, conjunctivitis, and asthma. The product has been available in the United States since the 1960s and is produced by several specialized manufacturers of allergenic extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juniperus scopulorum pollen extract.